Surrozen, Inc.SRZNEarnings & Financial Report
Surrozen, Inc. is a clinical-stage biotechnology company dedicated to developing targeted regenerative therapies based on the Wnt signaling pathway. Its product pipeline covers unmet medical needs in ophthalmology, gastrointestinal diseases and other severe chronic conditions, serving global patient groups and collaborating with industry partners to advance innovative treatment accessibility.
SRZN Q3 FY2024 Key Financial Metrics
Revenue
$10.0M
Gross Profit
N/A
Operating Profit
$1.2M
Net Profit
$-1.4M
Gross Margin
N/A
Operating Margin
12.3%
Net Margin
-14.3%
YoY Growth
N/A
EPS
$-0.44
Surrozen, Inc. Q3 FY2024 Financial Summary
Surrozen, Inc. reported revenue of $10.0M for Q3 FY2024, with a net profit of $-1.4M (up 86.3% YoY) (-14.3% margin).
Key Financial Metrics
| Total Revenue | $10.0M |
|---|---|
| Net Profit | $-1.4M |
| Gross Margin | N/A |
| Operating Margin | 12.3% |
| Report Period | Q3 FY2024 |
Surrozen, Inc. Quarterly Revenue & Net Profit History
Surrozen, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2024 | $10.0M | — | $-1.4M | -14.3% |
| Q2 FY2024 | $0 | — | $-25.3M | N/A |
| Q1 FY2024 | $0 | — | $-8.8M | N/A |
| Q3 FY2023 | $0 | — | $-10.4M | N/A |
Income Statement
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $10.0M |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|
| Assets | $54.0M | $36.7M | $45.1M | $48.0M |
| Liabilities | $8.4M | $6.6M | $39.0M | $42.3M |
| Equity | $45.5M | $30.1M | $6.1M | $5.7M |
Cash Flow
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|
| Operating CF | $-10.1M | $-8.7M | $-5.6M | $-6.8M |